Диссертация (1174280), страница 22
Текст из файла (страница 22)
B. Lambert‐eaton myasthenic syndrome and merkel cellcarcinoma/D.B. Simmons, T.M. Duginski, J.C. McClean et al.//Muscle & nerve. –2016. – Т. 53. – №. 2. – С. 325-326.154. Singman, E.L. Use of the Cogan lid twitch to identify myasthenia gravis /D.B.Simmons, T.M. Duginski, J.C. McClean et al.// Journal of Neuro-Ophthalmology.2011. № 3 (31). C. 239–240.155. Sletten, D. M. COMPASS 31: a refined and abbreviated CompositeAutonomic Symptom Score /D.M. Sletten, G.A. Suarez, P.A.
Low et al.//MayoClinic proceedings. – Elsevier, 2012. – Т. 87. – №. 12. – С. 1196-1201.142156. Stich, O. SOX1 antibodies in sera from patients with paraneoplasticneurological syndromes /O. Stich, E. Klages, P. Bischler et al.//Acta NeurologicaScandinavica. – 2012. – Т. 125. – №. 5. – С. 326-331.157. Stockbridge, N. Dynamics of intracellular calcium and its possiblerelationship to phasic transmitter release and facilitation at the frog neuromuscularjunction / N. Stockbridge, J.W.
Moore.//Journal of Neuroscience. – 1984. – Т. 4. –№. 3. – С. 803-811.158. Suarez, G. A. The Autonomic Symptom Profile: a new instrument to assessautonomic symptoms /G.A. Suarez, T.L. Opfer-Gehrking, K.P. Offord etal.//Neurology. – 1999. – Т. 52. – №. 3. – С. 523-523.159. Südhof, T.
C. Synaptotagmins: C2-domain proteins that regulate membranetraffic / T.C. Südhof, J. Rizo.//Neuron. – 1996. – Т. 17. – №. 3. – С. 379-388.160. Takamori, M. Synaptotagmin can cause an immune‐mediated model ofLambert‐Eaton myasthenic syndrome in rats /M. Takamori, T. Hamada, K. Komaiet al.//Annals of Neurology: Official Journal of the American NeurologicalAssociation and the Child Neurology Society. – 1994. – Т. 35. – №. 1. – С.
74-80.161. Takamori, M. Antibodies to recombinant synaptotagmin and calcium channelsubtypes in Lambert-Eaton myasthenic syndrome /M. Takamori, M. Takahashi, Y.Yasukawa et al.//Journal of the neurological sciences. – 1995. – Т. 133. – №.
1-2. –С. 95-101.162. Takamori, M. Lambert–Eaton myasthenic syndrome: search for alternativeautoimmune targets and possible compensatory mechanisms based on presynapticcalcium homeostasis / M. Takamori.//Journal of neuroimmunology. – 2008. – Т.201. – С. 145-152.163. Takamori, M. Lambert–Eaton myasthenic syndrome as an autoimmunecalcium channelopathy / M. Takamori.//Biochemical and biophysical researchcommunications. – 2004.
– Т. 322. – №. 4. – С. 1347-1351..164. Tani, T. Regulatory T cells in paraneoplastic neurological syndromes/T. Tani,K. Tanaka, J. Idezuka et al.//Journal of neuroimmunology. – 2008. – Т. 196. – №.1-2. – С. 166-169.165. Tarr, T. B. New calcium channel agonists as potential therapeutics inLambert–Eaton myasthenic syndrome and other neuromuscular diseases /T.B.143Tarr, G.
Valdomir, M. Liang et al.//Annals of the New York Academy of Sciences.– 2012. – Т. 1275. – №. 1. – С. 85-91.166. Tim, R. W. Lambert-Eaton myasthenic syndrome: electrodiagnostic findingsand response to treatment /R.W. Tim, J.M. Massey, S.D. Sanders. //Neurology. –2000. – Т. 54. – №. 11. – С. 2176-2178.167. Timmermann, C. ‘Just give me the best quality of life questionnaire’: theKarnofsky scale and the history of quality of life measurements in cancer trials /C.Timmermann.//Chronic illness.
– 2013. – Т. 9. – №. 3. – С. 179-190.168. Titulaer, M. J. The Lambert–Eaton myasthenic syndrome 1988–2008: aclinical picture in 97 patients /M.J. Titulaer, P.W. Wirtz, J.B. Kuks et al.//Journalof neuroimmunology. – 2008. – Т. 201. – С. 153-158.169. Titulaer, M. J. Antibodies to active zone protein ERC1 in Lambert–Eatonmyasthenic syndrome /M.J. Titulaer, M.G. Huijbers, A.F. Lipka et al.//Humanimmunology.
– 2013. – Т. 74. – №. 7. – С. 849-851.170. Titulaer, M. J. SOX antibodies in small-cell lung cancer and Lambert-Eatonmyasthenic syndrome: frequency and relation with survival /M.J. Titulaer, R.Klooster, M. Potman et al.//Journal of Clinical Oncology. – 2009. – Т. 27. – №. 26.– С. 4260-4267.171. Titulaer, M. J. Lambert–Eaton myasthenic syndrome: from clinicalcharacteristics to therapeutic strategies / M.J. Titulaer, B. Lang, J.J.G.M.Verschuuren.//The Lancet Neurology.
– 2011. – Т. 10. – №. 12. – С. 1098-1107.172. Titulaer, M. J. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome(LEMS) tumor association prediction score accurately predicts small-cell lungcancer in the LEMS /M.J. Titulaer, P. Maddison, J.K. Sont et al.//J Clin Oncol. –2011. – Т. 29. – №. 7. – С.
902-908.173. Titulaer, M. J. Screening for tumours in paraneoplastic syndromes: report ofan EFNS task force /M.J. Titulaer, R. Soffietti, J. Dalmau et al.//European Journalof Neurology. – 2011. – Т. 18. – №. 1. – С. 19-e3.174. Titulaer, M. J. Lambert-Eaton myasthenic syndrome favours prognosis ofsmall cell lung carcinoma /M.J. Titulaer, P.W. Wirtz, A.R. van der Slik etal.//Neuromuscular Disorders. – THE BOULEVARD, LANGFORD LANE,KIDLINGTON, OXFORD OX5 1GB, ENGLAND : PERGAMON-ELSEVIERSCIENCE LTD, 2006.
– Т. 16. – С. S180-S181.144175. Titulaer, M. J. Lambert–Eaton myasthenic syndrome: tumor versus nontumorforms / M.J. Titulaer, J.J.G.M. Verschuuren.//Annals of the New York Academy ofSciences. – 2008. – Т. 1132. – №. 1. – С. 129-134.176. Tobergte, D. R. A Multi-objective Tabu Search Algorithm for ConstrainedOptmisation Problems / D.R.
Tobergte, S. Curtis.//J. Chem. Inf. Model. – 2013. –Т. 53. – С. 1689-1699.177. Trachtenberg, A.Kh. Metastatic lung tumors. Clinical oncopulmonology/A.kh.Trachtenberg, V.I. Chissov. – М., 2000.– P. 543–557.178. Treister, R. Validation of the composite autonomic symptom scale 31(COMPASS‐31) in patients with and without small fiber polyneuropathy/ R.Treister, K. O'Neil, H.M. Downs et al.//European journal of neurology. – 2015. –Т. 22. – №.
7. – С. 1124-1130.179. Tschernatsch, M. Anti-SOX1 antibodies in patients with paraneoplastic andnon-paraneoplastic neuropathy /M. Tschernatsch, P. Singh, O. Gross et al.//Journalof neuroimmunology. – 2010. – Т. 226. – №. 1-2. – С. 177-180.180. Tsien, R. W.
Calcium channels in excitable cell membranes / R.W.Tsien.//Annual review of physiology. – 1983. – Т. 45. – №. 1. – С. 341-358.181. Ugarawal, S. K. Adenocarcinoma of the prostate and Eaton-Lambertsyndrome: a previously unreported association/ S.K. Ugarawal, B.R.P. Birch, G.F.Abercrombie.//Scandinavian journal of urology and nephrology. – 1995.
– Т. 29. –№. 3. – С. 351-353.182. Vernino, S. Autoantibodies to ganglionic acetylcholine receptors inautoimmune autonomic neuropathies /S. Vernino, P.A. Low, R.D. Fealey etal.//New England Journal of Medicine. – 2000. – Т. 343. – №. 12. – С. 847-855.183. Vincent, A. Evidence of underdiagnosis of myasthenia gravis in older people/A. Vincent, L. Clover, C.
Buckley et al.//Journal of Neurology, Neurosurgery &Psychiatry. – 2003. – Т. 74. – №. 8. – С. 1105-1108.184. Vincent, A. Molecular targets for autoimmune and genetic disorders ofneuromuscular transmission /A. Vincent, D. Beeson, B. Lang.//European Journalof Biochemistry. – 2000. – Т. 267.
– №. 23. – С. 6717-6728.185. Vincent, A. Autoimmunity to the voltage-gated calcium channel underlies theLambert-Eaton myasthenic syndrome, a paraneoplastic disorder /A. Vincent, B.145Lang, J. Newsom-Davis.//Trends in neurosciences. – 1989. – Т. 12. – №. 12. – С.496-502.186. Waterman, S. A. Effect of Lambert‐Eaton myasthenic syndrome antibodies onautonomic neurons in the mouse / S.A. Waterman, B.
Lang, J. Newsom‐Davis.//Annals of Neurology: Official Journal of the American NeurologicalAssociation and the Child Neurology Society. – 1997. – Т. 42. – №. 2. – С. 147156.187. Whitney, K. D. Autoimmunity and neurological disease: antibody modulationof synaptic transmission / K.D. Whitney, J.O. McNamara.//Annual review ofneuroscience. – 1999.
– Т. 22. – №. 1. – С. 175-195.188. Willcox, N. Increased frequency of IgG heavy chain marker Glm (2) andHLA-B8 in Lambert-Eaton myasthenic syndrome with and without associated lungcarcinoma /N. Willcox, A.G. Demaine, J. Newsom-Davis et al.//Humanimmunology. – 1985. – Т. 14. – №. 1. – С. 29-36.189. Wirtz, P. W. HLA class I and II in Lambert-Eaton myasthenic syndromewithout associated tumor /P.W. Wirtz, B.O.
Roep, G.T. Schreuder et al.//Humanimmunology. – 2001. – Т. 62. – №. 8. – С. 809-813.190. Wirtz, P. W. Differences in clinical features between the Lambert-Eatonmyasthenic syndrome with and without cancer: an analysis of 227 published cases/P.W. Wirtz, T.M. Smallegange, A.R. Wintzen et al.//Clinical neurology andneurosurgery. – 2002. – Т.
104. – №. 4. – С. 359-363.191. Wirtz, P. W. The epidemiology of myasthenia gravis, Lambert-Eatonmyasthenic syndrome and their associated tumours in the northern part of theprovince of South Holland /P.W. Wirtz, M.G. Nijnuis, M. Sotodeh et al.//Journalof neurology. – 2003. – Т. 250. – №. 6.
– С. 698-701.192. Wirtz, P. W. P/Q-type calcium channel antibodies, Lambert–Eatonmyasthenic syndrome and survival in small cell lung cancer /P.W. Wirtz, B. Lang,F. Graus et al.//Journal of neuroimmunology. – 2005. – Т. 164. – №. 1-2. – С. 161165.193. Wirtz, P. W.
The epidemiology of the Lambert-Eaton myasthenic syndromein the Netherlands /P.W. Wirtz, J.G. Van Dijk, P.A. Van Doorn et al.//Neurology.– 2004. – Т. 63. – №. 2. – С. 397-398.146194. Wirtz, P. W. Lambert–Eaton myasthenic syndrome has a more progressivecourse in patients with lung cancer/ P.W. Wirtz, A.R. Wintzen, J.J.Verschuuren.//Muscle & Nerve: Official Journal of the American Association ofElectrodiagnostic Medicine. – 2005. – Т. 32.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
